Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients
Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company announced today that it has commenced dosing in a phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/γ inhibitor with additional SIK3 activity) in patients with locally advanced or metastatic breast cancer. This multi-center, randomized phase II study is being conducted in eastern Europe and is designed to assess Tenalisib’s anti-tumor activity and safety across two dose levels.The study also includes translational assessments intended to delineate the effect of Tenalisib’s multivalent mechanism on relevant cytokines/chemokine levels and gene expression changes within the tumor microenvironment.
Rhizen indicated that Tenalisib, in addition to its selective dual PI3K δ/γ inhibitory activity, also has Salt-Inducible Kinase 3 (SIK3) activity via its principal metabolite, that could potentially contribute to its chemo-sensitization effect as observed in its preclinical studies, especially in breast cancer. Rhizen hopes to establish the single agent activity of Tenalisib in this current study after which it plans to expand the assessment across additional solid tumor indications and combinations both with chemotherapeutic agents and with immune-checkpoint inhibitors.
“PI3K inhibition continues to remain a relevant therapeutic intervention across tumor types given the importance of its signalling in tumor development. We have demonstrated our ability to develop safe and differentiated isoform selective PI3K inhibitors that can withstand the rigors of development and be integrated into clinical practice” said Swaroop Vakkalanka, Founder & CEO of Rhizen Pharma. Swaroop also added that “This is a sentinel study that we expect will pave the way for Tenalisib’s potential to be expanded beyond haematological cancers into solid tumors, given its stellar safety profile, multivalent activity and consequent combinability.”
About Tenalisib (RP6530):
Tenalisib (RP6530) is a highly selective, next-generation, orally active, dual PI3K δ/γ inhibitor with additional SIK3 activity, that is currently in phase II clinical development for haematological malignancies & solid tumors. Tenalisib has been granted US FDA Fast Track & Orphan-Drug Designations for treatment of r/r PTCL and CTCL and had recently published data from its phase II study evaluating Tenalisib both as monotherapy and in combination with Romidepsin in r/r PTCL & CTCL which showed robust responses of ~75% ORR in r/r PTCL and ~54% in r/r CTCL. The combination was well tolerated with no additional toxicities noted over & above those of the individual agents, confirming Tenalisib’s superior safety profile in its class. Overall, Tenalisib has been studied in over 165 patients across studies till now and has shown potentially better safety outcomes vis-à-vis other agents in the PI3K class.
About Rhizen Pharmaceuticals AG.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology & inflammation therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.
Rhizen has proven expertise in the PI3K modulator space with the discovery of our first PI3Kδ & CK1ε asset Umbralisib, that has been successfully developed & commercialized in MZL & FL by our licensing partner TG Therapeutics (TGTX) in USA. Beyond this, Rhizen has a deep oncology & inflammation pipeline spanning discovery to phase II clinical development stages.
Rhizen is headquartered in Basel, Switzerland. For additional information, please visit https://www.rhizen.com/
This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Rhizen Pharmaceuticals AG - Contact:
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals AG.
Telephone: +41 32 580 0113
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Names Dennis Maroney Master Perfumer30.11.2022 22:20:00 CET | Press release
IFF (NYSE: IFF) has named Dennis Maroney Master Perfumer, an honor recognizing his career achievements, entrepreneurial contributions and record of commercial excellence in the global perfumery industry. Maroney is a 32-year industry veteran and IFF’s ninth Master Perfumer, a distinction reserved for those who have demonstrated exceptional leadership and measurable impact in perfumery. “Dennis has demonstrated a unique ability to bring together science and creativity, with a strong, undefeatable sense of purpose,” said Frank Clyburn, CEO, IFF. “He is a humble leader and an inspiring mentor who has created milestone scent signatures in the beauty and home care world. His unique contributions to the products we use every day in our beauty and home care routines are truly inspiring, and this Master Perfumer recognition is more than deserved.” Commenting on his Master Perfumer appointment, Maroney said: “Perfumery is about transporting the consumer to a time and place where they are happy.
Digital Integrator Cohesive Group Acquires Vetasi, Leading Provider of IBM Maximo Managed Services30.11.2022 22:03:00 CET | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that its Cohesive Group digital integrator business has acquired Vetasi, a leading international consultancy specializing in enterprise asset management (EAM) solutions, with a strong focus on IBM Maximo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130006068/en/ Image courtesy - Getty Images Vetasi brings to Cohesive the largest IBM Maximo consultancy team across Europe, Africa, and ASEAN countries, with headquarters in the United Kingdom and operations based in Poland, Indonesia, South Africa, Spain, Ukraine, and Australia. In addition to EAM resources, Vetasi deepens the Cohesive team with additional strategic advisory capabilities and adds to the Cohesive services catalog Maximo cloud hosting capabilities, expertise in low-code development, and strong real estate and facilities management domain knowledge. B
Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape30.11.2022 18:47:00 CET | Press release
SoftServe, a leader in digital services and consulting, has been recognized as an Aspirant in Everest Group's Life Sciences Digital Services PEAK Matrix® Assessment 2022. Everest Group is a provider of strategic research insights on IT, business processes, and engineering services and a global Business Process Outsourcing (BPO) research firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005890/en/ Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape (Graphic: Business Wire) The Life Sciences Digital Services PEAK Matrix® Assessment 2022 covers the top digital life sciences service providers, best-in-class solutions and products, and top locations, according to Everest Group's research. This is the first time SoftServe has been named in the Life Sciences sector. SoftServe debuted with an impressive score in Everest Group's two assessment areas: vision and strategy a
Leading Payments Innovator Chooses Verimatrix XTD Technology to Bolster Cybersecurity30.11.2022 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Norway-based Tidypay, a provider of enterprise-level payment solutions that are flexible enough for businesses of all sizes, selected Verimatrix Extended Threat Defense (XTD) technologies to protect and monitor the apps that power its solutions. A top European payment services provider that aims to greatly simplify the payment journey, Tidypay looked to Verimatrix XTD to strengthen security for its Tidypay One, Tidypay eCom and Tidypay GO solutions that serve as the backbones of its many services, including integrated POS systems, accounting systems and individual mobile standalone devices. Through Verimatrix XTD, the company, its partners and users benefit from proven defenses against application repackaging, debuggers, dynamic modification, emulators, reverse engineering, and more. “Verimatrix shares our vision of efficiency and sim
IWBI Launches the WELL Equity Rating to Advance Organizations and Places Where “Everyone Feels Welcome, Seen and Heard”30.11.2022 17:27:00 CET | Press release
The International WELL Building Institute (IWBI) announced today the launch of the WELL Equity Rating, a new rating designed to help organizations act on their diversity, equity, inclusion and accessibility goals, and improve company culture and employee health. Over 30 leading organizations – including AvalonBay Communities, Canderel, Empire State Realty Trust, JLL, Overbury, Shaw Industries and the State University of New York (SUNY) College of Environmental Science and Forestry – have already enrolled in the rating, demonstrating their commitment to creating places where everyone has an equalopportunity to thrive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005749/en/ (Graphic: Business Wire) By providing an evidence-based roadmap, the WELL Equity Rating empowers organizations to better address the needs of marginalized and underserved populations and take an action-oriented approach to creating equitable, people
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom